# Nuclide record tlx-591 (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/tlx-591/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "tlx-591" ;
  schema:name "Lutetium-177 rosopatamab tetraxetan"@en ;
  schema:alternateName "TLX591"@en, "TLX591-Tx"@en, "177Lu-rosopatamab tetraxetan"@en ;
  schema:description "A cancer-targeting antibody carrying a radioactive metal is being tested as a two-dose treatment for advanced prostate cancer, on top of the usual hormone or chemotherapy drugs."@en ;
  schema:url <https://nuclide.cc/drugs/tlx-591/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://telixpharma.com/news-views/first-patient-dosed-in-phase-iii-prostact-global-study-of-antibody-based-prostate-cancer-therapy-candidate-tlx591/>, <https://telixpharma.com/news-views/prostact-global-phase-3-study-part-1-achieves-primary-objectives/>, <https://telixpharma.com/wp-content/uploads/2024/05/TLX_ProstACT_SELECT_Study_of_TLX591_rADC_Therapy_Positive_rPFS.pdf>, <https://clinicaltrials.gov/study/NCT06520345> ;
  nuclide:status "phase-3" ;
  nuclide:tag "PSMA", "radio-antibody-drug conjugate", "prostate cancer", "phase 3" ;
  nuclide:modality "radioimmunotherapy" ;
  nuclide:related <https://nuclide.cc/drugs/illuccix/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate-mcrpc/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioimmunotherapy/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> ;
  nuclide:companies <https://nuclide.cc/companies/telix/> ;
  nuclide:trials <https://nuclide.cc/trials/nct06520345/> .